Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study

Background: Results on overall survival in randomised studies of mono- versus combination chemotherapy in advanced colorectal cancer patients may have been biased by an imbalance in salvage treatments. This is the first randomised study that evaluates sequential versus combination chemotherapy with a fluoropyrimidine, irinotecan and oxaliplatin. Patients and methods: A total of 820 patients were randomised between first-line capecitabine, second-line irinotecan and third-line capecitabine + oxaliplatin (arm A) versus first-line capecitabine + irinotecan, and second-line capecitabine + oxalipla... Mehr ...

Verfasser: Koopman, M.
Antonini, N. F.
Douma, J.
Wals, J.
Honkoop, A. H.
Erdkamp, F. L. G.
de Jong, R. S.
Rodenburg, C. J.
Vreugdenhil, G.
Akkermans-Vogelaar, J. M.
Punt, C. J. A.
Dokumenttyp: TEXT
Erscheinungsdatum: 2006
Verlag/Hrsg.: Oxford University Press
Schlagwörter: original article
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-26631924
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : http://annonc.oxfordjournals.org/cgi/content/short/mdl179v1